Brain ischemia
Drug research and approvals for brain ischemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 777 studies of brain ischemia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 777
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Improving Endovascular Treatment Through Process RefinementsNCT07948694 · Not applicable · Beijing Tiantan Hospital · starts Apr 15, 2026
- Evalutation of Ocular Symptoms in Asymptomatic Carotid Artery StenosisNCT07949006 · Not reported · University of Bologna · starts Jan 1, 2027
- Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling DeficitsNCT07944261 · Phase 3 · Shandong Provincial Hospital · starts Oct 15, 2026
- MRS Imaging Evaluation for Acute Minor StrokeNCT07945158 · Not reported · Shanghai Jiao Tong University Affiliated Sixth People's Hospital · starts Aug 3, 2024
- A Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke PatientsNCT07943065 · Not reported · University Hospitals Coventry and Warwickshire NHS Trust · starts Sep 16, 2026
- Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis: A…NCT07935408 · Not reported · Second Affiliated Hospital of Soochow University · starts Mar 1, 2026
- Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation StrokeNCT07933692 · Phase 4 · Shandong Provincial Hospital · starts Oct 1, 2021
- Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler (TCD) for the Occurrence of…NCT07932080 · Not applicable · CHC Montlegia · starts Dec 1, 2026
- Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial StenosisNCT07932639 · Phase 4 · Second Affiliated Hospital of Soochow University · starts Mar 21, 2026
Phase 3 6
- Epoetin betaErythropoietin receptor agonist
- Sulfur hexafluorideDiagnostic agent
- AlteplaseTissue-type plasminogen activator exogenous protein
- AbciximabIntegrin alpha-IIb/beta-3 inhibitor
- Citicoline
- Nerinetide
Phase 2 5
- Autologous cord blood
- XenonDiagnostic agent
- Darbepoetin alfaErythropoietin receptor agonist
- TopiramateCarbonic anhydrase II inhibitor
- TenecteplaseTissue-type plasminogen activator exogenous protein
Phase 1 or earlier 7
- MelatoninMelatonin receptor agonist
- ClonidineAdrenergic receptor alpha-2 agonist
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- CaffeineAdenosine receptor antagonist
- Nitric oxideSoluble guanylate cyclase activator
- GlenzocimabPlatelet glycoprotein VI (GPVI) inhibitor
- DexmedetomidineAdrenergic receptor alpha-2 agonist
How its trials ended
375 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 63 whose ending is known, 38% met their primary endpoint, 8% missed it and 54% stopped early.
- Completed, result not reported15441%
- Ongoing10327%
- Status unknown5515%
- Met its primary endpoint246%
- Stopped: other or unclear154%
- Stopped: enrollment or feasibility103%
- Stopped: lack of efficacy62%
- Missed its primary endpoint51%
- Stopped: sponsor or business decision31%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA